AbbVie Inc., US00287Y1091

Piper Sandler lifts target as AbbVie stock trades at EUR 259.60, down 1.37%

Published on 11/19/2026 at 08:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Piper Sandler raised its AbbVie price target to USD 349 from USD 303 and maintained an Overweight rating. On Xetra, the stock closed at EUR 263.20 on Wednesday, November 18, 2026.

What investors are watching

  • Piper Sandler raised its AbbVie price target to USD 349 from USD 303 and kept an Overweight rating on November 18.
  • The firm cited AbbVie's growth outlook and greater visibility for Skyrizi combination products in inflammatory bowel disease.
  • AbbVie remains under scrutiny for pipeline execution and the durability of its immunology franchise.
AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

AbbVie stock traded at EUR 259.60 on Lang & Schwarz at 08:54 CET on Thursday, November 19, 2026, 1.37 percent below the Xetra close of EUR 263.20 on Wednesday, November 18.

Analyst target moves higher

Markets Insider reported on Wednesday that Piper Sandler lifted its 12-month price target for AbbVie to USD 349 from USD 303 while retaining an Overweight rating. The firm pointed to AbbVie's top-line and EBITDA growth profile through the end of the decade.

Piper Sandler also sees scope for multiple expansion, citing greater visibility around Skyrizi-containing combination products for inflammatory bowel disease. The comments put the focus on the durability of AbbVie's immunology franchise and on how its pipeline can support growth beyond established products.

Pipeline execution remains central

For investors, the analyst action adds a fresh reference point after AbbVie's third-quarter update. The main questions remain the pace of prescription growth, the performance of newer products and the company's ability to advance late-stage programs through clinical and regulatory milestones.

Broader sentiment will also shape the trading backdrop for US equities. Follow the S&P 500 for the wider market context.

More news and analyses on AbbVie stock.

Disclaimer...
en | US00287Y1091 | ABBVIE INC. | boerse | 70534576 | bgmi